)
Pharmaceuticals major Zydus Group today announced receipt of approval to sell chronic pain reliever morphine sulfate tablets from the US Food and Drug Administration (USFDA).
"The product used in treatment of chronic pain or cancer related pain will be manufactured at Nesher Pharmaceuticals (USA) LLC, located at St Louis," the Cadila Healthcare, a part of Zydus group, said in a filing to the BSE.
A subsidiary of Zydus Pharmaceuticals Inc, Nesher has considerable expertise in niche therapies with development or products barrier, such as controlled release medications, it added.
Shares of Cadila Healthcare were trading at Rs 1,839 per scrip in mid-day trade, up 2.34 per cent from previous close on the BSE.
